dc.contributor.author | Oksanen Pia | |
dc.contributor.author | Koskinen Inka | |
dc.contributor.author | Eronen Heli | |
dc.contributor.author | Huhtala Heini | |
dc.contributor.author | Jussila Airi | |
dc.contributor.author | Kolehmainen Sara | |
dc.contributor.author | Sipponen Taina | |
dc.contributor.author | Koffert Jukka | |
dc.contributor.author | Ilus Tuire | |
dc.date.accessioned | 2022-10-27T12:27:49Z | |
dc.date.available | 2022-10-27T12:27:49Z | |
dc.identifier.uri | https://www.utupub.fi/handle/10024/158770 | |
dc.description.abstract | <p><strong>Background and aims: </strong>Therapy with two concomitant biologicals targeting different inflammatory pathways has emerged as a new therapy option for treatment refractory inflammatory bowel disease (IBD). Data on the efficacy and safety of dual biological therapy (DBT) are scarce and are investigated in this study.</p><p><strong>Materials and methods: </strong>Data on all patients treated with a combination of two biologicals in four Finnish tertiary centres were collected and analysed. Remission was assessed by a physician on the basis of biomarkers, endoscopic evaluation and alleviation of symptoms.</p><p><strong>Results: </strong>A total of 16 patients with 22 trials of DBT were included. Fifteen patients had Crohn's disease. The most common combination of DBT was adalimumab (ADA) and ustekinumab (USTE; 36%) with median follow-up of nine months (range 2-31). Altogether seven (32%) patients were in remission at the end of follow-up and in two trials response to DBT was assessed to be partial with the relief of patient symptoms. In a total of four trials DBT reduced the need for corticosteroids. The majority of patients achieving a response to DBT were treated with the combination of ADA and USTE (56%). At the end of follow-up all nine (41%) patients responding to DBT continued treatment. Infection complications occurred in three patients (19%).</p><p><strong>Conclusion: </strong>DBT is a promising alternative treatment for refractory IBD, and half of our patients benefitted from it. More data on the efficacy and safety of DBT are needed especially in long-term follow up.</p> | |
dc.language.iso | en | |
dc.publisher | Taylor and Francis [Commercial Publisher] | |
dc.title | Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study | |
dc.identifier.urn | URN:NBN:fi-fe2022081153947 | |
dc.contributor.organization | fi=kliinisen laitoksen yhteiset|en=Department of Clinical Medicine| | |
dc.contributor.organization | fi=tyks, vsshp|en=tyks, vsshp| | |
dc.contributor.organization | fi=sisätautioppi|en=Internal Medicine| | |
dc.contributor.organization-code | 2607300 | |
dc.contributor.organization-code | 2607318 | |
dc.converis.publication-id | 174791578 | |
dc.converis.url | https://research.utu.fi/converis/portal/Publication/174791578 | |
dc.identifier.eissn | 1502-7708 | |
dc.identifier.jour-issn | 0036-5521 | |
dc.okm.affiliatedauthor | Koffert, Jukka | |
dc.okm.affiliatedauthor | Dataimport, tyks, vsshp | |
dc.okm.discipline | 3121 Sisätaudit | fi_FI |
dc.okm.discipline | 3121 Internal medicine | en_GB |
dc.okm.internationalcopublication | not an international co-publication | |
dc.okm.internationality | International publication | |
dc.okm.type | Journal article | |
dc.publisher.country | United Kingdom | en_GB |
dc.publisher.country | Britannia | fi_FI |
dc.publisher.country-code | GB | |
dc.relation.doi | 10.1080/00365521.2022.2045350 | |
dc.relation.ispartofjournal | Scandinavian Journal of Gastroenterology | |
dc.year.issued | 2022 | |